pravibismane

Pravibismane is a first-in-class, broad-spectrum anti-infective small molecule developed by Microbion. It demonstrates potent activity against a wide range of multidrug-resistant bacteria and biofilms, which are common in chronic infections such as diabetic foot ulcers (DFU), orthopedic infections, and lung diseases including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Pravibismane acts as a microbial bioenergetic inhibitor, rapidly disrupting cellular bioenergetics to halt bacterial growth without immediate cell lysis. Its mechanism includes antibiofilm and anti-inflammatory activities. The drug has shown efficacy in reducing wound size and ulcer-related amputations in clinical studies, with minimal systemic absorption when used topically. Pravibismane is currently in Phase 2 development for chronic wounds and orthopedic infections, with inhaled formulations advancing into Phase 1 for chronic lung diseases[1][3][4][5][6].

Other names

pravibismane1,2-(bis(1,3-dithia-2-bismolane)thio)ethane1,2-bis((1,3-dithia-2-bismolan-2-yl)thio)ethane1,3,2-dithiabismolane, 2,2'-(1,2-ethanediylbis(thio))bis2,2'-(1,2-diylbis(sulfanediyl))bis(1,3,2-dithiabismolane)